Serum Omentin-1 Levels in Diabetic and Nondiabetic Patients with Chronic Kidney Disease

Abstract

Background: Omentin-1, a novel adipokine identified in visceral adipose tissue, is negatively correlated with different conditions such as diabetes, obesity and inflammation. However, changes in serum Omentin levels associated with the degree of the renal dysfunction and metabolic risk factors in CKD patients has not yet been revealed. In the present study, we aimed to investigate the level of Omentin-1 and related para­meters in diabetic and non-diabetic CKD patients.

Methods: 64 (30 diabetic, 34 non-diabetic) CKD patients and 27 healthy control subjects enrolled in this cross-sectional study. Anthropometric and laboratory assessment performed and malnutrition and inflammation components evaluated. Serum concentrations of Omentin-1 and insulin were measured by using ELISA.

Results: Serum Omentin-1 levels in CKD patients were significantly lower compared to the healthy controls. Further analyze revealed that decreased omentin in CKD patients was due to the reduced omentin levels in the diabetic subgroup. An increase in inflammation and malnutrition components was correlated with a decrease in the serum level of Omentin. Omentin levels were lower in stage 2 and 3 CKD but not stage 4 CKD patients compared to control.

Conclusions: The results of the present study suggest that diabetes mellitus and inflammation should be associated with lower omentin levels in CKD population; however, this reduction resolves due to the failure of degradation and excretion of omentin when creatinine clearance falls below 30 ml/min (stage 4 CKD).

Key words

omentin - chronic kidney disease - diabetes mellitus - inflammation

• References

• 1 Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. American journal of kidney diseases: the official journal of the National Kidney Foundation 1998; 32: S112-S119
• 2 Vanholder R, Massy Z, Argiles A et al. Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transpl 2005; 20: 1048-1056
• 3 Akdag I, Yilmaz Y, Kahvecioglu S et al. Clinical value of the malnutrition-inflammation-atherosclerosis syndrome for long-term prediction of cardiovascular mortality in patients with end-stage renal disease: a 5-year prospective study. Nephron Clinical practice 2008; 108: c99-c105
• 4 Tripepi G, Mattace Raso F, Sijbrands E et al. Inflammation and asymmetric dimethylarginine for predicting death and cardiovascular events in ESRD patients. Clinical journal of the American Society of Nephrology: CJASN 2011; 6: 1714-1721
• 5 Shoji T, Masakane I, Watanabe Y et al. Committee of Renal Data Registry JSfDT. Elevated non-high-density lipoprotein cholesterol (non-HDL-C) predicts atherosclerotic cardiovascular events in hemodialysis patients. Clinical journal of the American Society of Nephrology: CJASN 2011; 6: 1112-1120
• 6 Flier JS. Obesity wars: molecular progress confronts an expanding epidemic. Cell 2004; 116: 337-350
• 7 de Souza Batista CM, Yang RZ, Lee MJ. et al. Omentin plasma levels and gene expression are decreased in obesity. Diabetes 2007; 56: 1655-1661
• 8 Pan HY, Guo L, Li Q. Changes of serum omentin-1 levels in normal subjects and in patients with impaired glucose regulation and with newly diagnosed and untreated type 2 diabetes. Diabetes research and clinical practice 2010; 88: 29-33
• 9 Tan BK, Adya R, Farhatullah S et al. Omentin-1, a novel adipokine, is decreased in overweight insulin-resistant women with polycystic ovary syndrome – Ex vivo and in vivo regulation of omentin-1 by insulin and glucose. Diabetes 2008; 57: 801-808
• 10 Kazama K, Usui T, Okada M et al. Omentin plays an anti-inflammatory role through inhibition of TNF-alpha-induced superoxide production in vascular smooth muscle cells. European Journal of Pharmacology 2012; 686: 116-123
• 11 Shibata R, Ouchi N, Takahashi R et al. Omentin as a novel biomarker of metabolic risk factors. Diabetol Metab Syndr 2012; 4
• 12 Auguet T, Quintero Y, Riesco D et al. New adipokines vaspin and omentin. Circulating levels and gene expression in adipose tissue from morbidly obese women. BMC medical genetics 2011; 12: 60
• 13 Zhong X, Zhang HY, Tan H et al. Association of serum omentin-1 levels with coronary artery disease. Acta pharmacologica Sinica 2011; 32: 873-878
• 14 Liu R, Wang XL, Bu PL. Omentin-1 is associated with carotid atherosclerosis in patients with metabolic syndrome. Diabetes research and clinical practice 2011; 93: 21-25
• 15 Shibata R, Takahashi R, Kataoka Y et al. Association of a fat-derived plasma protein omentin with carotid artery intima-media thickness in apparently healthy men. Hypertension research: official journal of the Japanese Society of Hypertension 2011; 34: 1309-1312
• 16 Matthews DR, Hosker JP, Rudenski AS et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419
• 17 Assoc AD. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2012; 35: S64-S71
• 18 Levey AS, Bosch JP, Lewis JB et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Annals of internal medicine 1999; 130: 461-470
• 19 Pecoits-Filho R, Lindholm B, Stenvinkel P. The malnutrition, inflammation, and atherosclerosis (MIA) syndrome – the heart of the matter. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association – European Renal Association 2002; 17 (Suppl. 11) 28-31
• 20 Brunzell JD, Hokanson JE. Dyslipidemia of central obesity and insulin resistance. Diabetes Care 1999; 22: C10-C13
• 21 Yang RZ, Lee MJ, Hu H et al. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am J Physiol-Endoc M 2006; 290: E1253-E1261
• 22 Schaffler A, Neumeier M, Herfarth H et al. Genomic structure of human omentin, a new adipocytokine expressed in omental adipose tissue. Biochimica et biophysica acta 2005; 1732: 96-102
• 23 Yamawaki H, Tsubaki N, Mukohda M et al. Omentin, a novel adipokine, induces vasodilation in rat isolated blood vessels. Biochemical and biophysical research communications 2010; 393: 668-672
• 24 Yoo HJ, Hwang SY, Hong HC et al. Association of circulating omentin-1 level with arterial stiffness and carotid plaque in type 2 diabetes. Cardiovascular diabetology 2011; 10: 103
• 25 Choi JH, Rhee EJ, Kim KH et al. Plasma omentin-1 levels are reduced in non-obese women with normal glucose tolerance and polycystic ovary syndrome. European journal of endocrinology/European Federation of Endocrine Societies 2011; 165: 789-796
• 26 Tan BK, Pua S, Syed F et al. Decreased plasma omentin-1 levels in Type 1 diabetes mellitus. Diabetic medicine: a journal of the British Diabetic Association 2008; 25: 1254-1255
• 27 Tan BK, Adya R, Randeva HS. Omentin: A Novel Link Between Inflammation, Diabesity, and Cardiovascular Disease. Trends Cardiovas Med 2010; 20: 143-148
• 28 Moreno-Navarrete JM, Ortega F, Castro A et al. Circulating Omentin as a Novel Biomarker of Endothelial Dysfunction. Obesity 2011; 19: 1552-1559
• 29 Moreno-Navarrete JM, Catalan V, Ortega F et al. Circulating omentin concentration increases after weight loss. Nutrition & metabolism 2010; 7: 27
• 30 Shaker M, Mashhadani ZI, Mehdi AA. Effect of Treatment with Metformin on Omentin-1, Ghrelin and other Biochemical, Clinical Features in PCOS Patients. Oman medical journal 2010; 25: 289-293
• 31 Alcelik A, Tosun M, Ozlu MF et al. Serum levels of omentin in end-stage renal disease patients. Kidney Blood Press Res 2012; 35: 511-516
• 32 Shinohara K, Shoji T, Emoto M et al. Insulin resistance as an independent predictor of cardiovascular mortality in patients with end-stage renal disease. J Am Soc Nephrol 2002; 13: 1894-1900
• 33 Zanetti M, Barazzoni R, Guarnieri G. Inflammation and insulin resistance in uremia. Journal of renal nutrition: the official journal of the Council on Renal Nutrition of the National Kidney Foundation 2008; 18: 70-75
• 34 Oberg BP, McMenamin E, Lucas FL et al. Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney international 2004; 65: 1009-1016
• 35 Mathur S, Devaraj S, Jialal I. Accelerated atherosclerosis, dyslipidemia, and oxidative stress in end-stage renal disease. Current opinion in nephrology and hypertension 2002; 11: 141-147
• 36 El-Mesallamy H, El-Derany M, Hamdy N. Serum omentin-1 and chemerin levels are interrelated in patients with Type 2 diabetes mellitus with or without ischaemic heart disease. Diabetic Medicine 2011; 28: 1194-1200
• 37 Tan BK, Adya R, Farhatullah S et al. Metformin Treatment May Increase Omentin-1 Levels in Women With Polycystic Ovary Syndrome. Diabetes 2010; 59: 3023-3031
• 38 Zhong X, Li X, Liu F et al. Omentin inhibits TNF-alpha-induced expression of adhesion molecules in endothelial cells via ERK/NF-kappaB pathway. Biochemical and biophysical research communications 2012; 425: 401-406
• 39 Schaffler A, Zeitoun M, Wobser H et al. Frequency and significance of the novel single nucleotide missense polymorphism Val109Asp in the human gene encoding omentin in Caucasian patients with type 2 diabetes mellitus or chronic inflammatory bowel diseases. Cardiovascular diabetology 2007; 6: 3
• 40 Senolt L, Polanska M, Filkova M et al. Vaspin and omentin: new adipokines differentially regulated at the site of inflammation in rheumatoid arthritis. Ann Rheum Dis 2010; 69: 1410-1411